Safety of switching from brand-name to generic levetiracetam in patients with epilepsy
Magdalena Bosak, Agnieszka Słowik, Wojciech Turaj Department of Neurology, Jagiellonian University Medical College, Kraków, Poland Purpose: The approach to the use of generic antiepileptic drugs has recently evolved from major concern to general acceptance, but the evidence related specifically to t...
Saved in:
Main Authors: | Bosak M (Author), Słowik A (Author), Turaj W (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2017-08-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Public Health Outcomes May Differ After Switching from Brand-Name to Generic Angiotensin II Receptor Blockers
by: Jacinthe Leclerc, et al.
Published: (2020) -
Evaluating Therapeutic Equivalence of Generic and Original Levetiracetam in Patients with Epilepsy: A Retrospective Study
by: Jannapas Tharavichitkun, et al.
Published: (2022) -
The concept of: Generic drugs and patented drugs Vs brand name drugs and non-proprietary (generic) name drugs.
by: Karan eThakkar, et al.
Published: (2013) -
Evaluating the bioequivalence of levetiracetam brand and generic oral tablets available in the Saudi market in vivo
by: Danah ALRabeeah, et al.
Published: (2023) -
Comparison of Pharmaceutical Characteristics between Brand-Name Meropenem and Its Generics
by: Ping Yang, et al.
Published: (2021)